Clinical Trial Update: Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating metronomic oral vinorelbine in combination with tislelizumab for EGFR/ALK-negative advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: EGFR/ ALK-negative Advanced NSCLC | Phase 2 | Status: UNKNOWN